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Quercetin prevents liver carcinogenesis by inducing cell
cycle arrest, decreasing cell proliferation and enhancing
apoptosis
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Scope: Quercetin is the most abundant flavonoid in human diet. It has special interest as it
holds anticancerous properties. This study aims to clarify the mechanisms involved in quercetin
effects during the occurrence of preneoplastic lesions in rat liver.
Methods and results: Adult male Wistar rats were subjected to a two-phase model of hepato-
carcinogenesis (initiated-promoted group). Initiated-promoted animals also received quercetin
10 and 20 mg/kg body weight (IPQ10 and IPQ20 groups, respectively). Antioxidant defenses
were modified by quercetin administration at both doses. However, only IPQ20 group showed a
reduction in number and volume of preneoplastic lesions. This group showed increased apop-
tosis and a reduction in the proliferative index. In addition, IPQ20 group displayed a reduction
of cell percentages in G1 and S phases, accumulation in G2, and decrease in M phase, with re-
duced expression of cyclin D1, cyclin A, cyclin B, and cyclin-dependent kinase 1. Interestingly,
peroxisome proliferator activated receptor- levels were reduced in IPQ20 group.
Conclusion: The outcomes of this study represent a significant contribution to the current
understanding on the preventive mechanisms of quercetin during the early stages of liver cancer
development, demonstrating that in addition to its known proapoptotic characteristics, the
flavonoid modulates the expression of critical cell cycle regulators and peroxisome proliferator
activated receptor- activity.
Keywords:
Apoptosis / Preneoplastic liver / Proliferation / Quercetin
Received: May 17, 2013
Revised: July 4, 2013
Accepted: July 9, 2013
 Additional supporting information may be found in the online version of this article atthe publisher’s web-site
Correspondence: Dr. Marı́a de Luján Alvarez, Instituto de
Fisiologı́a Experimental (IFISE-CONICET), Facultad de Ciencias
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1 Introduction
Hepatocellular carcinoma (HCC) is the sixth most common
neoplasm and the third most frequent cause of cancer death,
after lung and colon cancer [1]. In humans, liver preneoplas-
tic lesions emerge weeks or months before the diagnosis of
hepatocellular adenomas and HCCs [2]. A similar progres-
sion is reproduced by chemicals in laboratory rats [3], leading
to the development of a number of systems to study liver
neoplasia in vivo [4]. The initiation-promotion or two-stage
model of cancer development mimics the events of the latent
SOD, superoxide dismutase; TBARS, thiobarbituric acid reactive
substances
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period of human hepatocarcinogenesis and represents a very
useful tool to study molecular mechanisms occurring during
the early stages of liver cancer. Diethylnitrosamine (DEN) is a
genotoxic carcinogen widely used as chemical initiator in ro-
dent models of experimental hepatocarcinogenesis [5]. DEN
is a well-known contaminant present in tobacco smoke, water,
preserved meats, fried meals, agricultural chemicals, cosmet-
ics, and pharmaceutical products [6]. Following the initiation
stage, the administration of promoting agents, such as
2-acetylaminofluorene (2-AAF), causes selective enhance-
ment of the proliferation of initiated hepatocytes over
noninitiated cells [7]. Although the coordination of cell
replication and apoptosis is maintained in normal liver
tissue, the disruption in this balance that takes place in
precancerous and cancerous tissues is considered one of the
hallmarks of cancer [8, 9].
Quercetin (3,3′,4′,5,7-pentahydroxylflavone) is the most
abundant flavonoid present in the plant kingdom as a sec-
ondary metabolite. It is found in a variety of human foods
such as grapes, apples, red onions, cherries, broccoli, berries,
tea, citrus fruits, and capers. Average daily uptake varies
between 10 and 100 mg depending on eating habits. Most
quercetin is present in plants as hydrophilic glycosides that
are not easily absorbed. Because quercetin is also available
in highly purified extracts, daily uptakes of 500–1000 mg/day
can be easily achieved using selected dietary supplements.
In these purified forms, quercetin aglycone bioavailability
is quite high [10]. Quercetin and related flavonoids have at-
tracted much attention as potential anticarcinogens. The dose
levels of quercetin required for anticancer activity are much
higher than those achieved with daily intakes from the diet.
These doses of quercetin would be attainable with the con-
sumption of supplements containing the pure aglycone at
high concentrations [10, 11].
It has been reported that quercetin has chemopreventive
effects in a hepatocarcinogenic model, in part by reducing
DEN-associated oxidative stress generation [12] and in part
by inducing apoptosis of initiated cells at 24 h after DEN
treatment [13]. Besides, in a medium-term bioassay of DEN-
induced hepatic preneoplastic lesions, quercetin reduced the
incidence of liver foci by reducing p53 expression and de-
creasing apoptosis [14]. Evidently, the molecular mechanisms
involved in the preventive effects of quercetin in liver cancer
appear to be complex. In the present study, we attempt to
clarify additional mechanisms involved in quercetin anticar-
cinogenic effects during the early stage of neoplastic occur-
rence in rat liver, and we centered the focus on the balance
between cell proliferation and apoptosis.
2 Materials and methods
2.1 Chemicals
DEN, 2-AAF, and quercetin were obtained from Sigma
Chemical Co. (St. Louis, MO, USA). Anti-pi class of rat
glutathione S-transferase (rGST P) antibody was purchased
from Stressgen Bioreagents (Ann Arbor, MI, USA). Cy3
fluorescent secondary antibody was from Jackson Im-
munoResearch Laboratories, Inc. (West Grove, PA, USA).
Antibodies against procaspase-3, Bax, Bcl-2, cytochrome c,
proliferating cell nuclear antigen (PCNA), cyclin D1, cyclin
E, cyclin A, cyclin B1, cyclin-dependent kinase 1 (cdk1), cdk2,
and p53 were from Santa Cruz Biotechnology (Santa Cruz,
CA, USA). Anti-peroxisome proliferator activated receptor-
(PPAR-) antibody was from Abcam Inc. (Cambridge, MA,
USA). Pierce-enhanced chemiluminescence (ECL) Western
Blotting Substrate was from Thermo Fisher Scientific
(Rockford, IL, USA). All other chemicals were of the highest
grade commercially available.
2.2 Animals and treatments
Adult male Wistar rats weighing 330–380 g were maintained
in a room at constant temperature with a 12 h light–dark cycle,
with food and water supplied ad libitum. Experimental pro-
tocols were performed according to the NIH “Guide for the
Care and Use of Laboratory Animals” (Publication no. 25–28,
revised 1996) and approved by the local animal care and use
committee. Animals were divided in groups of —six to seven
rats each. A scheme of the experimental protocol is shown
in Fig. 1. Rats from the initiated-promoted (IP) group were
subjected to a two-phase model of rat hepatocarcinogenesis,
as described previously [15]. Briefly, animals received two
intraperitoneal necrogenic doses of DEN (150 mg/kg body
weight) 2 wk apart. One week after the last injection, the rats
received 20 mg/kg body weight of 2-AAF by gavage for 4 con-
secutive days per week during 3 wk. Animals from IP group
also received quercetin 10 and 20 mg/kg body weight (IPQ10
and IPQ20 groups, respectively), administered by gavage 2 h
before each injection of DEN and 2 h before each week of
promotion treatment. Quercetin was dissolved in an aqueous
solution containing 0.5% carboxymethylcellulose. Addition-
ally, control rats (C group) received only the vehicles of the
drugs or quercetin at 10 and 20 mg/kg body weight (CQ10
and CQ20 groups, respectively). All animals were sacrificed at
the end of the 6th wk and livers were removed and processed.
2.3 Immunohistochemical observations
2.3.1 Confocal immunofluorescence analysis
Liver tissues were fixed in 10% v/v formalin solution and
embedded in low-melting paraffin. Sections of 5 m thick-
ness were incubated with primary antibody (anti rGST P,
1:100) in a humidified chamber at 4C overnight. Sub-
sequently, fluorescent dye conjugated secondary antibody
(dilution 1:100) was used. Nuclei were counterstained using
4′,6-diamidino-2-phenylindole (dilution 1:100). Detection of
bound antibody was accomplished by immunofluorescence
C© 2013 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim www.mnf-journal.com
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Figure 1. Scheme showing the experi-
mental protocol used in this study. Male
Wistar rats were subjected to a two-phase
model of hepatocarcinogenesis. IP group
received two intraperitoneal doses of
DEN (150 mg/kg body weight) 2 wk apart.
One week after the last injection, the an-
imals received 20 mg/kg body weight of
2-AAF by gavage during four consecutive
days per week during 3 wk. IPQ10 and
IPQ20 groups were subjected to the same
protocol and also received quercetin (10
and 20 mg/kg body weight, respectively)
by gavage 2 h before each DEN injec-
tion and 2 h before each week of promo-
tion treatment. Control (C group) received
only the vehicles of the drugs or quercetin
at 10 and 20 mg/kg body weight (CQ10
and CQ20 groups, respectively).
in a Nikon C1 Plus microscope (Nikon, Tokyo, Japan). Slides
were also stained in the absence of primary antibodies to
evaluate nonspecific secondary antibodies reactions.
2.3.2 Quantitation of preneoplastic foci
rGST P has been described as the most effective single
marker of hepatic preneoplasia in the rat [16]. Consequently,
immunohistochemical detection of this isozyme is the most
widely used method for identification and quantitation of rat
preneoplastic foci [17]. The stained liver images were quanti-
fied using ImageJ analysis software (U.S. National Institutes
of Health, Bethesda, MD, USA). The number of preneoplas-
tic foci per liver and the percentage of liver occupied by foci
were calculated according to the modified Saltykov’s method
[18].
2.3.3 Determination of proliferative index
To investigate differences in proliferation activity among the
experimental groups, liver slides were examined by immuno-
histochemical staining with anti-PCNA antibody, determined
by the method of Greenwell et al. [19]. In order to differenti-
ate proliferative cells inside the foci and in the surrounding
tissue, consecutive section slides were stained with anti-rGST
P [20]. The PCNA proliferative index was defined as the num-
ber of proliferative cells (in G1, S, G2, and M phases) per 100
hepatocytes counted in ten high-power fields.
The percentages of PCNA-positive preneoplastic hepato-
cytes in each phase of the cell cycle were also calculated [15].
2.4 Lipid peroxidation assay
Lipid peroxidation is considered as an indirect measure of ox-
idative stress [21]. The amount of aldehydic products gener-
ated by lipid peroxidation in liver homogenates was quantified
by the thiobarbituric acid reaction according to the method of
Ohkawa et al. [22] and measured by HPLC [23]. The amount
Q4
of thiobarbituric acid reactive substances (TBARS) was ex-
pressed as percentage of C group.
2.5 Caspase-3 activity assay
Caspase-3 activity was determined using EnzChek1 Caspase-
3 Assay Kit #1 (Molecular Probes Inc., Eugene, OR, USA),
according to the manufacturer’s suggestions. Briefly, cytoso-
lic fractions from each sample were mixed with substrate
solution. Fluorescence was measured at an excitation wave-
length of 360 nm and an emission wavelength of 465 nm
in a DTX 880 multimode detector (Beckman Coulter Inc.,
Fullerton, CA, USA).
2.6 Liver tissue antioxidant capacity
Reduced (GSH) and oxidized (GSSG) glutathione were deter-
mined in total liver homogenates according to the protocol
described by Tietze [24], and GSH/GSSG ratio was calcu-
lated. Catalase (CAT) activity was determined by monitor-
ing the rate of decomposition of H2O2 as a function of de-
crease in absorbance at 240 nm [20]. Superoxide dismutase
(SOD) gel activity assay was based on the method of Donahue
et al. [25]. Bands quantification was made by densitometry us-
ing the Gel-Pro Analyzer (Media Cybernetics, Silver Spring,
MD, USA) software.
2.7 Western blot analysis
Tissue samples were homogenized in 300 mM sucrose with
protease inhibitors. Cytosolic, mitochondrial, and nuclear
extracts were prepared as described previously [15, 26].
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Protein concentration was determined by the Lowry
method [27]. Equal amounts of protein were subjected to
electrophoresis on 12% SDS-polyacrylamide gels and trans-
ferred to PVDF membranes (PerkinElmer Life Sciences,
Boston, MA, USA). Membranes were blocked with PBS-10%Q5
nonfat milk, washed and incubated overnight at 4C with
primary antibodies. Finally, membranes were incubated
with peroxidase-conjugated secondary antibodies and bands
were detected by the ECL detection system and quantified
by densitometry using the Gel-Pro Analyzer software. Equal
loading and protein transference were checked by Ponceau
S staining of the membranes.
2.8 RNA isolation, cDNA synthesis, and real-time
q-PCR
Total RNA was isolated from rat liver tissues by the TriZOL
method (Life Technologies Inc., Gaithersburg, MD, USA)
according to manufacturer’s instructions. cDNA was made
from 1 g of the total RNA using an oligo-dT primer and
M-MLV reverse transcriptase (Promega, Madison, WI, USA).
The PCR reactions were performed using an Mx3000P Real-
Time Thermocycler (Stratagene, La Jolla, CA, USA) with
SYBR Green I (Invitrogen, Carlsbad, CA, USA) as a fluo-
rescent dye. PCR reactions were initiated with incubation at
95C for 2 min, followed by 40 cycles at 95C for 15 s, 60C
for 30 s, and 72C for 40 s. For each sample, we analyzed
glyceraldehyde-3P-dehydrogenase (Gapdh) expression to nor-
malize target gene expression. Primer sequences, with their
corresponding amplification efficiency, are available online as
Supporting Information Table 1. Gene-specific amplification
was confirmed by a single peak in the melting curve analysis.
Relative changes in gene expression were determined using
the 2-Ct method [28].
2.9 Statistical analysis
Results were expressed as mean ± SE. Significance in dif-
ferences was tested by one-way ANOVA, followed by Tukey’s
test. Differences were considered significant when the p value
was < 0.05.
3 Results
Since CQ10 and CQ20 groups did not show any differences
between them throughout the study, from now on, we will
refer to both quercetin control groups as a single group (CQ).
3.1 Effect of quercetin on number and volume of
preneoplastic foci
We assessed the effect of quercetin treatments on number
and volume of rGST P-positive foci. As expected, neither pre-
Figure 2. Effect of quercetin on number and volume of liver pre-
neoplastic foci. (A) Representative images of rGST P-positive pre-
neoplastic foci obtained by confocal microscopy (objective: 10×).
C and CQ livers displayed no rGST P staining (data not shown).
Changes in (B) number of liver lesions per liver and (C) volume
percentage of the liver occupied by preneoplastic foci are repre-
sented for IP, IPQ10, and IPQ20 groups. IP: rats with liver preneo-
plasia; IPQ10: IP rats treated with quercetin 10 mg/kg body weight;
IPQ20: IP rats treated with quercetin 20 mg/kg body weight. Data
are expressed as mean ± SE; n ≥ 4. #p < 0.05 versus IP.
neoplastic foci nor initiated hepatocytes were observed in
control rats treated with quercetin or with the vehicles (data
not shown). On the other hand, animals subjected to the
initiation-promotion model displayed preneoplastic lesions
that were quantified. Representative images from IP, IPQ10,
and IPQ20 groups are shown in Fig. 2A. Quercetin at the
dose of 10 mg/kg body weight administered to IP animals
did not induce any changes in number or volume of liver
foci. However, both parameters were significantly decreased
in IPQ20 group as compared to IP animals. Quercetin treat-
ment at 20 mg/kg body weight reduced the total number of
initiated cells capable of developing into focal clones (–50%,
Fig. 2B) and the growth rate and total cellular population of
preneoplastic foci (–52.5%, Fig. 2C).
3.2 Analysis of lipid peroxidation and antioxidant
capacity
Preneoplastic treatment induced a 30% increase in the gener-
ation of TBARS as compared to control animals. In animals
carrying hepatic lesions induced by DEN/2-AAF treatment,
quercetin administration produced a decrease in TBARS lev-
els (both IPQ10 and IPQ20 groups); reaching control values
(Fig. 3A). Also, GSH/GSSG ratio, and CAT and Cu/Zn SOD
activities were analyzed. No changes in GSH/GSSG ratio
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Figure 3. Analysis of lipid peroxidation
and liver antioxidant capacity. (A) Lipid
peroxidation was determined by quan-
tification of the amount of thiobarbi-
turic acid reactive substances (TBARS).
(B) Determination of GSH/GSSG ratio
in liver homogenates from the exper-
imental groups. Analysis of (C) cata-
lase (CAT) and (D) Cu/Zn superox-
ide dismutase (SOD) activities in to-
tal liver homogenates. C: control rats;
CQ: C rats treated with quercetin; IP:
rats with liver preneoplasia; IPQ10: IP
rats treated with quercetin 10 mg/kg
body weight; IPQ20: IP rats treated with
quercetin 20 mg/kg body weight. Data
are expressed as percentage of C group
and are mean ± SE; n ≥ 4. *p < 0.05
versus C; #p < 0.05 versus IP.
were observed between treatments (Fig. 3B). On the other
hand, CAT activity was significantly decreased (Fig. 3C) and
Cu/Zn SOD activity significantly increased (Fig. 3D) in IP an-
imals whereas quercetin treatment abolished these changes.
3.3 Effect of quercetin on programmed cell death
Apoptosis is orchestrated by activation of the caspase cas-
cade and effector caspase-3 is the ultimate responsible for the
majority of the effects [29]. Figure 4A shows that caspase-3 ac-
tivity was significantly increased in IP group with respect to C
animals. This result was expected, since rates of apoptosis are
higher in the preneoplastic liver than in the normal tissue [8].
Moreover, when quercetin was administered at 20 mg/kg
body weight, apoptosis was enhanced as caspase-3 activity
was significantly increased in IPQ20 group relative to IP ani-
mals. In association with these results, levels of procaspase-3
(inactive precursor of caspase-3) were measured by Western
blot and showed a decrease in IPQ20 rats (Fig. 4A, right
panel).
Since the fate of the cells (survival or death) is largely de-
pendent on the mitochondrial Bax/Bcl-2 ratio [31], we mea-
sured mitochondrial Bax and Bcl-2 levels and calculated the
aforementioned ratio. Figure 4B shows that Bax/Bcl-2 ratio
was significantly increased in IP animals as compared to C
group. Treatment with quercetin at 20 mg/kg body weight
significantly augmented Bax/Bcl-2 ratio in IPQ20 relative to
IP group. Furthermore, levels of cytosolic cytochrome c were
increased in IPQ20 group compared to IP animals (Fig. 4C).
Together, these results support the fact that apoptosis is en-
hanced in rats treated with quercetin at 20 mg/kg body weight
and the mitochondrial pathway is involved in this process.
3.4 Effect of quercetin on the proliferative status
of liver foci
Figure 5A shows representative images for immunohisto-
chemical detection of PCNA-positive cells. As shown in
Fig. 5B, control livers (both C and CQ groups) showed a
very low incidence of cell replication, in line with the qui-
escent status of normal adult liver [33]. In animals carrying
hepatic lesions, proliferative indexes were determined both
inside and surrounding the foci. As expected, proliferative sta-
tus inside the foci was notably increased with respect to the
surrounding tissue. In addition, whereas the IPQ10 group
did not show differences in the proliferative index with re-
spect to the IP group, treatment with quercetin at 20 mg/kg
body weight induced a significant diminution of proliferative
C© 2013 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim www.mnf-journal.com
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Figure 4. Effect of quercetin on apoptotic cell death. (A) Caspase-
3 activity was determined in cytosolic fractions and expressed
as percentages, being C group considered 100%. Additionally,
procaspase-3 levels were evaluated by Western blot (right panel).
(B) Mitochondrial levels of pro-apoptotic Bax and anti-apoptotic
Bcl-2 proteins were analyzed by Western blot. After densitometric
quantitation, Bax/Bcl-2 ratio was calculated, and results were ex-
pressed as percentage of C group. (C) Release of cytochrome
c was determined by Western blot in cytosolic extracts from
each experimental group. C: control rats; CQ: C rats treated with
quercetin; IP: rats with liver preneoplasia; IPQ10: IP rats treated
with quercetin 10 mg/kg body weight; IPQ20: IP rats treated with
quercetin 20 mg/kg body weight. Results are expressed as per-
centage, considering control as 100%. -Actin and prohibitin were
probed as loading control in cytosolic and mitochondrial extracts,
respectively. Data are mean ± SE; n ≥ 4. *p < 0.05 versus C;
#p < 0.05 versus IP.
Figure 5. Effect of quercetin on proliferative status of liver foci.
(A) Representative images of proliferating cell nuclear antigen
(PCNA)-positive cells obtained by optical microscopy (objective:
20×). (B) Changes in the proliferative index in the whole liver
(C and CQ groups), differentiated between the foci and the sur-
rounding tissue (IP, IPQ10, and IPQ20 groups). (C) Determination
of the percentage of preneoplastic hepatocytes in each phase of
the cell cycle. C: control rats; CQ: C rats treated with quercetin; IP:
rats with liver preneoplasia; IPQ10: IP rats treated with quercetin
10 mg/kg body weight; IPQ20: IP rats treated with quercetin
20 mg/kg body weight. Data are expressed as mean ± SE; n ≥ 4.
#p < 0.05 versus IP.
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index both inside the foci (–25%) and in the surrounding
tissue (–50%). Changes in nontumor host tissue support the
fact that this tissue is far from being “normal,” and it might
even play an important role in the pathogenesis of the disease
or it may contribute to the tumor-suppressive effects of some
anticancer agents [34].
Additionally, we determined the percentages of preneo-
plastic hepatocytes in each phase of the cell cycle (Fig. 5C).
We observed a significant diminution of the percentages of
cells in G1 and S phases in the IPQ20 group, which could be
explained by a lower entrance of preneoplastic cells into the
cell cycle. In addition, a significant accumulation of cells in
G2 phase was also observed in the IPQ20 group. Accordingly,
this group showed a diminution in the percentage of cells in
M phase.
3.5 Effect of quercetin on the expression of cell cycle
related genes
Real-Time q-PCR studies revealed several fold increments
of cell cycle related genes in rats carrying liver preneoplasia
compared to control animals, in accordance with the prolif-
erative status of preneoplastic liver and the quiescent status
of normal liver (Fig. 6A). In animals with hepatic lesions,
treatment with quercetin at 20 mg/kg body weight signifi-
cantly prevented the increased expression of genes encoding
for cyclin D1 (Ccnd1), cyclin A2 (Ccna2), cyclin B1 (Ccnb1),
and cdk1. In addition, treatment with quercetin at 20 mg/kg
body weight induced a significant increment in mRNA lev-
els of the cell cycle regulator p53 (Tp53) relative to IP group.
IPQ10 group did not show any significant differences in gene
expression with respect to IP group (Fig. 6A).
In accordance with these results, Western blot studies
revealed reduction of cyclin D1, cyclin A, cyclin B1, and cdk1
proteins levels and a significant increase in p53 protein level
in IPQ20 group relative to IP group (Fig. 6B).
3.6 Effect of quercetin on peroxisome proliferator
activated receptor- (PPAR-)
In the past few years, it has been demonstrated that quercetin
is a selective inhibitor of PPAR- that binds directly to the
receptor and competes with its ligands for binding [35]. Thus,
we hypothesized that quercetin treatment may affect PPAR-
 expression as another mechanism that contributes to the
preventive effects of the flavonoid.
Results showed that hepatic PPAR- protein expression
was increased in animals with liver preneoplasia, compared
to control rats. In addition, when quercetin was adminis-
tered at a dose of 10 mg/kg body weight (IPQ10), no effect in
PPAR- protein levels was observed; however, treatment with
quercetin at 20 mg/kg body weight produced a significant at-
tenuation of PPAR- protein levels (Fig. 7A). We also studied
hepatic PPAR- mRNA (Ppara) expression and observed a
similar profile as for protein expression, with a significant in-
crement of Ppara in IP group with respect to control animals
and a diminution in IPQ20 rats (Fig. 7B).
Additionally, we measured the transcription levels of
PPAR--target genes: Acox1, Acsl1, and Cpt1a [36]. Results
showed that the hepatic expression of these genes was in-
duced in IP animals. This induction was reverted in IPQ20
group, reaching control levels (Fig. 7C).
4 Discussion
Quercetin, the most abundant flavonoid in the diet, is consid-
ered one of the most promising compounds for disease pre-
vention and therapy; however, many of its effects still need
to be studied [10, 11]. In addition, both cytoprotective and
cytotoxic effects of quercetin were described in diverse cell
culture models [37, 38]. Regarding cell proliferation, a dual
effect of quercetin has been reported: the flavonoid stimu-
lates or inhibits cell proliferation in vitro, at physiologically
relevant concentrations [39]. These differential effects may
depend on the presence of estrogen receptor  and its ratio
to the estrogen receptor , a parameter that varies between
different tissues [40]. So, given both beneficial and adverse
effects of quercetin, it is assumed that its prevalent action
depends on the cell type or tissue, the presence of a stressor,
and the dose of the flavonoid used.
Particularly in cancer, considerable in vitro and in vivo data
indicate that quercetin acts as an anticarcinogen agent [11,41].
Numerous in vitro investigations have reported the effects of
quercetin on signal transduction pathways associated with
the process of carcinogenesis. They include effects on cell cy-
cle regulation, apoptosis, proinflamatory protein induction,
and angiogenesis [11]. Thus, the molecular mechanisms in-
volved in the preventive effects of quercetin in cancer appear
to be complex [12–14]. For this reason, we attempt to provide
new data on these mechanisms in early liver carcinogene-
sis, focusing on the balance between cell proliferation and
apoptosis.
The present study was conducted using quercetin agly-
cone. This is not the form in which the flavonoid is available
in the regular diet (usually as glycosides), but it is the main
form present in purified dietary supplements. It has been
reported that the effects of quercetin as an anticarcinogen
are generally observed for the aglycone, but not for the gly-
coside form [11]. We tested two doses of quercetin (10 and
20 mg/kg body weight) and we observed that in the IPQ10
group there was no reduction of preneoplastic foci. How-
ever, the IPQ20 group showed a significant reduction in both
number and volume of hepatic lesions. Other studies have
reported quercetin effectiveness in reducing hepatic lesions
with doses of the aglycone form ranging from 5 to 25 mg/kg
body weight [12,14]. It has been postulated that prevention of
DEN-induced liver foci development by quercetin is because
the flavonoid reduces lipid peroxidation levels and strength-
ens the endogenous antioxidant defense system during the
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Figure 6. Effect of quercetin on the expression of some cell cycle related genes. (A) Real-time q-PCR analysis of genes encoding for: cyclin
D1 (Ccnd1), cyclin E1 (Ccne1), cyclin A2 (Ccna2), cyclin B1 (Ccnb1), cyclin-dependent kinase 2 (Cdk2), cyclin-dependent kinase 1 (Cdk1),
and tumor protein p53 (Tp53). (B) Western blot analysis of cell cycle related proteins: cyclin D1, cyclin E, cyclin A, cyclin B1, cdk2, cdk1,
and p53. C: control rats; CQ: C rats treated with quercetin; IP: rats with liver preneoplasia; IPQ10: IP rats treated with quercetin 10 mg/kg
body weight; IPQ20: IP rats treated with quercetin 20 mg/kg body weight. Data are expressed as ratio/percentage of C group and are mean
± SE; n ≥ 4. *p < 0.05 versus C; #p < 0.05 versus IP.
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Figure 7. Effect of quercetin on hepatic PPAR- expression. (A)
Expression levels of hepatic PPAR- protein by Western blot anal-
ysis. (B) mRNA levels of PPAR- (Ppara) by real-time q-PCR. (C)
Transcription levels of PPAR--target genes: acyl-coenzyme A oxi-
dase 1, palmitoyl (Acox1), acyl-CoA synthetase long-chain family
member 1 (Acsl1), and carnitine palmitoyltransferase 1a, liver
(Cpt1a). C: control rats; CQ: C rats treated with quercetin; IP:
rats with liver preneoplasia; IPQ10: IP rats treated with quercetin
10 mg/kg body weight; IPQ20: IP rats treated with quercetin
20 mg/kg body weight. Data are expressed as ratio/percentage
of C group and are mean ± SE; n ≥ 4. *p < 0.05 versus C;
#p < 0.05 versus IP.
initial hours after DEN injection [12, 42]. In our work, we
studied lipid peroxidation levels and antioxidant enzymes ac-
tivities at the end of the experimental protocol. Given the
prooxidant nature of the genotoxic treatment, it is reasonable
that IP animals showed alterations in TBARS levels and in
the antioxidant capacities, with respect to control rats. Admin-
istration of quercetin (both IPQ10 and IPQ20) maintained
these parameters similar to those in control rats. Similar re-
sults have been previously published [12]. Notably, quercetin
at 10 mg/kg body weight maintained its antioxidant prop-
erties but lacked its antiproliferative and proapoptotic activi-
ties; these properties are key in decreasing preneoplastic foci
growth.
Apoptosis is another mechanism that could be modulated
by quercetin. Numerous in vitro studies in HCC cell lines
have reported the modulatory action of quercetin on several
key components of signaling pathways linked to apoptotic cell
death [32,43,44]. In vivo studies in liver preneoplasia models
have shown that quercetin induced apoptosis by increasing
caspases-9 and -3 at 24 h post DEN initiation [13], whereas in
a medium-term assay the flavonoid inhibited apoptotic cell
death [14]. These discrepancies about the effect of quercetin
on apoptosis could depend on the experimental models. In the
present work, quercetin at 20 mg/kg body weight increased
caspase-3 activity, indicating that the programmed cell death
is activated with the treatment. Furthermore, quercetin in-
duced an increase in mitochondrial Bax/Bcl-2 ratio. It is
known that this ratio determines cell survival or cell death af-
ter apoptotic stimuli [31]. Due to the translocation of proapop-
totic Bax to the mitochondrial membrane in the IPQ20 group,
cytochrome c is released from mitochondria to cytosol, lead-
ing to executioner caspases activation. In the present work,
we describe the ability of quercetin to modulate proteins of
the Bcl-2 family in vivo, and it seems that this mechanism is
operating as a preventive action of the flavonoid during the
development of liver lesions.
Premalignant lesions and even some neoplastic tumors
are highly dependent of chemical promotion and responsive
to treatments that decrease proliferation and increase apopto-
sis [45]. Therefore, targeting one or both of these events may
result in the reversion of cell growth. In this context, we ana-
lyzed whether quercetin was able to affect cell proliferation by
targeting cyclins and cdks that command each phase of the
cell cycle, as another possible feature of the preventive action
of the flavonoid. IPQ20 group showed a significant reduction
in the proliferative status both inside the foci and in the sur-
rounding tissue. Cell cycle distribution of preneoplastic hep-
atocytes displayed a diminution of cells in G1 and S phases
of the cell cycle, which may be attributed in part to a minor
entrance of preneoplastic cells into the cell cycle, and in part
to the increase of apoptosis. Induction of cyclin D1 regulates
the progression through G1 phase and also G1/S transition;
therefore, this protein is considered the “rate-limiting” step
in hepatocyte proliferation [46]. In line with previous studies
in different cell types [47–49], the increased cyclin D1 expres-
sion observed in animals with proliferative foci was prevented
by quercetin administration, resulting in diminution of pre-
neoplastic cells in G1 and S phases. We have also observed
that quercetin induced a significant accumulation of preneo-
plastic cells in G2 phase, indicating a major effect in G2/M
transition. This action of quercetin has only been described in
cultured cells [50–52]. The initiation of mitosis is controlled
by the activation of the cyclin B/cdk1 complex, so reduced cy-
clin B1 protein levels can induce G2 arrest [53], and inhibition
of cyclin B1 transcription causes cell cycle arrest. Treatment
with quercetin during the development of liver preneoplastic
lesions prevented the increases of both cyclin B1 and cdk1.
Although only mRNA and protein levels of cyclin B1 and
cdk1 were measured, it is clear that the lack of increment
in IPQ20 group with respect to IP animals does not favor
cyclin B/cdk1 complex formation. In addition, prevention of
the increase of cyclin A mRNA and protein levels was also
observed. Cyclin A is particularly interesting among the cy-
clin family because it functions in both S phase and mitosis,
depending on its cdk partner [54, 55]. So, the prevention of
cyclin A increase by quercetin may have a double impact on
preneoplastic cell proliferation: there could be a reduction in
the passage into the S phase and also a decrease into M phase
entry.
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In addition, p53 (both transcript and protein) was aug-
mented in quercetin-treated animals carrying preneoplastic
foci, a result that was predictable since p53 has a pivotal role
in cell cycle regulation and apoptosis. Additional studies are
required to define if changes in critical cell cycle regulators
induced by quercetin are a consequence of a direct effect of
the flavonoid or an indirect action via p53 induction.
Finally, quercetin can act as an inhibitor of PPAR- by
binding directly to the receptor and competing with its lig-
ands [35]. We analyzed the effects of quercetin on PPAR
expression and activation and observed a significant inhibi-
tion of PPAR- activation in the IPQ20 group. Interestingly,
the 10 mg/kg body weight dose did not reduce preneoplas-
tic foci incidence and neither did inhibit PPAR- activation.
We made some additional experiments using MK886, a non-
competitive inhibitor of PPAR- [55] and found that MK886
effectively blocked PPAR- activation, reduced number and
volume of preneoplastic foci, and decreased cell proliferation
by inducing cell cycle arrest in G2/M (data not shown). These
results led us to assume that inhibition of PPAR- activation
is a key event in the preventive action of quercetin on geno-
toxic neoplastic occurrence in rat liver. Additional studies
using PPAR--knock-down animals are necessary to confirm
this hypothesis.
In conclusion, the present work provides new data con-
cerning the mechanisms involved in the preventive actions of
quercetin during the development of liver cancer. In addition
to its proapoptotic properties, quercetin is able to modulate
the expression of critical cell cycle regulators and PPAR-
activation. These actions affect the proliferation of preneo-
plastic hepatocytes that finally conduct to a reduction of liver
lesions.
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